$67.9M in CY2024 Part D spend42K claims · 5K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Rufinamide used for?
1 I NDICATIONS AND USAGE BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
Is there a generic for Rufinamide?
Yes. 23 ANDAs filed at FDA, 11 generic manufacturers currently shipping.
How much does my plan pay for Rufinamide?
Across 329 Part D plans, Rufinamide averages $0.852/unit (NADAC). Lowest available: $0.263/unit. Highest in distribution: $1.51/unit.
Is Rufinamide on the FDA shortage list?
No. Rufinamide is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.